Robert W. Baird Initiates Coverage on Enliven Therapeutics (NASDAQ:ELVN)

Robert W. Baird started coverage on shares of Enliven Therapeutics (NASDAQ:ELVN) in a research report released on Tuesday, Marketbeat Ratings reports. The firm issued an outperform rating and a $32.00 price target on the stock.

Separately, Mizuho began coverage on shares of Enliven Therapeutics in a research report on Tuesday, April 9th. They issued a buy rating and a $34.00 price target for the company.

Enliven Therapeutics Stock Down 1.5 %

NASDAQ:ELVN opened at $21.70 on Tuesday. The company has a fifty day moving average of $21.20 and a 200-day moving average of $16.99. The firm has a market capitalization of $1.02 billion, a P/E ratio of -11.24 and a beta of 1.11. Enliven Therapeutics has a twelve month low of $9.80 and a twelve month high of $26.00.

Enliven Therapeutics (NASDAQ:ELVN) last posted its quarterly earnings results on Tuesday, May 14th. The company reported ($0.54) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.58) by $0.04. On average, analysts anticipate that Enliven Therapeutics will post -2.26 EPS for the current fiscal year.

Insiders Place Their Bets

In other Enliven Therapeutics news, insider Joseph P. Lyssikatos sold 12,000 shares of Enliven Therapeutics stock in a transaction on Monday, April 1st. The shares were sold at an average price of $18.60, for a total transaction of $223,200.00. The transaction was disclosed in a filing with the SEC, which is available through this link. In related news, CFO Benjamin Hohl sold 4,250 shares of the business’s stock in a transaction dated Tuesday, May 28th. The shares were sold at an average price of $23.18, for a total value of $98,515.00. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Joseph P. Lyssikatos sold 12,000 shares of the business’s stock in a transaction dated Monday, April 1st. The stock was sold at an average price of $18.60, for a total transaction of $223,200.00. The disclosure for this sale can be found here. Insiders have sold 1,289,171 shares of company stock valued at $28,682,066 in the last three months. 29.20% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Enliven Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the stock. AJOVista LLC bought a new stake in Enliven Therapeutics in the 4th quarter valued at about $28,000. China Universal Asset Management Co. Ltd. bought a new stake in shares of Enliven Therapeutics during the fourth quarter valued at about $66,000. Exchange Traded Concepts LLC increased its position in shares of Enliven Therapeutics by 34.0% during the fourth quarter. Exchange Traded Concepts LLC now owns 8,708 shares of the company’s stock valued at $121,000 after buying an additional 2,208 shares during the period. EntryPoint Capital LLC bought a new stake in shares of Enliven Therapeutics during the first quarter valued at about $167,000. Finally, Mirae Asset Global Investments Co. Ltd. increased its position in shares of Enliven Therapeutics by 9.1% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 12,305 shares of the company’s stock worth $170,000 after purchasing an additional 1,029 shares during the last quarter. 95.08% of the stock is owned by hedge funds and other institutional investors.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.